Список литературы
1. Силачев Д.Н., Плотников Е.Ю., Горюнов К.В., Романов А.Ю., Плосконос М.В.,
2. Долгушина Н.В., Николаев А.А., Зоров Д.Б., Сухих Г.Т. Роль полиаминов в жизнедеятельности клеток репродуктивной системы // Цитология. 2018. Т. 60. №3. С.164-172.
3. Lima A.R., Pinto J., Bastos M.L., Carvalho M., Guedes de Pinho P. NMR-based metabolomics studies of human prostate cancer tissue. Metabolomics. 2018. V. 14. no.1. P 88-92.
4. Li B., Liang J., Hanfrey C.C., Phillips M.A., Michael A.J. Discovery of ancestral L-ornithine and L-lysine decarboxylases reveals parallel, pseudoconvergent evolution of polyamine biosynthesis. J. Biol. Chem. 2021. V. 297. no. 4. P.
5. Плосконос М.В., Николаев А. А. Удержание свободных полиаминов в спермоплазме фертильных и субфертильных мужчин // Проблемы репродукции. 2010. Т. 16. № 3. С. 80-83.
6. Lenis Y.Y., Elmetwally M.A., Maldonado-Estrada J.G., Bazer F.W. Physiological importance of polyamines. Zygote. 2017. no. 3. P. 244-255.
7. Litwin M.S., Tan H.J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017. V. 317. no. 6. P.
8. Van der Graaf M., Schipper R.G., Oosterhof G.O., Schalken J.A., Verhofstad A.A., Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA. 2000. V. 10. P. 153-159.
9. Vourtsis D., Lamprou M., Sadikoglou E., Giannou A., Theodorakopoulou O., Sarrou E., Magoulas G.E., Bariamis S.E., Athanassopoulos C.M., Drainas D., Papaioannou D., Papadimitriou E. Effect of an all-trans-retinoic acid conjugate with spermine on viability of human prostate cancer and endothelial cells in vitro and angiogenesis in vivo. Eur. J. Pharmacol. 2013. V. 698. no. 1-3. P. 122-130.
10. Pietila M., Lampinen A., Pellinen R., Alhonen L. Inducible expression of antizyme 1 in prostate cancer cell lines after lentivirus mediated gene_transfer. Amino Acids. 2012. V. 42. no. 3. P. 559-564.
11. Bachmann A.S., Geerts D. Polyamine synthesis as a target of MYC oncogenes. J. Biol. Chem. 2018. V. 293. no. 48. P. 18757-18769.
12. Origanti S., Nowotarski S.L., Carr T.D., Sass-Kuhn S., Xiao L., Wang J.Y., Shantz L.M. Ornithine decarboxylase mRNA is stabilized in an mTORC1-dependent manner in Ras-transformed cells. Biochem. J. 2012.V. 442. no. 1. Р. 199-207.
13. Ou Y., Wang S.J., Li D., Chu B., Gu W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl. Acad. Sci. U S A. 2016. V. 113. no. 44. P. E6806-E6812.
14. Zabala-Letona A., Arruabarrena-Aristorena A., Martin-Martin N., Fernandez-Ruiz S., Sutherland J.D., Clasquin M., Tomas-Cortazar J., Jimenez J., Torres I., Quang P. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017. V. 547. no. 7661. P. 109-113.
15. Martinucci B., Cucielo M.S., Minatel B.C., Cury S.S., Caxali G.H., Aal M.C.E., Felisbino S.L., Pinhal D., Carvalho R.F., Delella F.K. Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines. Front Vet. Sci. 2022. V. 11. no. 9. P.
16. Sanford E.J., Drago J.R., Rohner T.J., Kessler G.F., Sheehan L., Lipton A. Preliminary evaluation of urinary polyamines in the diagnosis of genitourinary tract malignancy. J. Urol. 1975. V. 113. no. 2. P. 218-221.
17. Fair W.R., Wehner N., Brorsson U. Urinary polyamine levels in the diagnosis of carcinoma of the prostate. J. Urol. 1975. V. 114. no. 1. P.88-92.
18. Sugimoto M., Hiramatsu K., Kamei S., Kinoshita K., Hoshino M., Iwasaki K., Kawakita M. Significance of urinary N1,N8-diacetylspermidine and N1,N12-diacetylspermine as indicators of neoplastic diseases. J. Cancer Res. Clin. Oncol. 1995. V. 121. no. 2. P. 317-319.
19. Hiramatsu K., Sugimoto M., Kamei S., Hoshino M., Kinoshita K., Iwasaki K., Kawakita M. Diagnostic and prognostic usefulness of N1,N8-diacetylspermidine and N1,N12-diacetylspermine in urine as novel markers of malignancy. J. Cancer Res. Clin. Oncol. 1997. V. 123. no. 10. P. 539-545
20. Tsoi T.H., Chan C.F., Chan W.L., Chiu K.F., Wong W.T., Ng C.F., Wong K.L. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS ONE 2016. V. 11.no. 9.
21. Chiu P.K., Fung Y.H., Teoh J.Y., Chan C.H., Lo K.L., Li K.M., Tse R.T., Leung C.H., Wong Y.P., Roobol M.J., et al. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2021. V. 24. no. 2. P.542-548.
22. Goodwin A.C., Jadallah S., Toubaji A., Lecksell K., Hicks J.L., Kowalski J., Bova G.S., De Marzo A.M., Netto G.J., Casero R.A., Jr. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate. 2018. V. 68. no. 7. P. 766-772.
23. Shukla-Dave A., Castillo-Martin M., Chen M., Lobo J., Gladoun N., Collazo-Lorduy A., Khan F.M., Ponomarev V., Yi Z., Zhang W. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. Am. J. Pathol. 2016. V. 186. no. 12. P. 3131-3145.
24. Peng Q., Wong C.Y., Cheuk I.W., Teoh J.Y., Chiu P.K., Ng C.F. The Emerging Clinical Role of Spermine in Prostate Cancer Int. J. Mol. Sci. 2021. V. 22. no. 9. P. 4382.
25. Zaletok S.P., Klenov O.O., Bentrad V.V., Prylutskyi M.P., Vitruk Y.V., Stakhovsky E.O., Timoshenko A.V. Polyamines as new potential biomarkers for differential diagnosis of prostate cancer and estimation of its aggressiveness. Exp. Oncol. 2022. V. 44. no. 2. P. 148-154.
26. Tse R.T., Wong C.Y., Chiu P.K., Ng C.F. The Potential Role of Spermine and Its Acetylated Derivative in Human Malignancies. Int. J. Mol. Sci. 2022. V. 23. no. 3. P. 1258-1266.
27. Huang W., Eickhoff J.C., Mehraein-Ghomi F., Church D.R., Wilding G., Basu H.S. Expression of spermidine/spermine N(1)-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015. V. 75. no. 11. P. 1150-1159.
28. Thomas M.A., Nagarajan R., Huda A., Margolis D., Sarma M.K., Sheng K., Reiter R.E., Raman S.S. Multidimensional MR spectroscopic imaging of prostate cancer in vivo. NMR Biomed. 2014. V. 27. No. 1. P. 53-66.
29. Maxeiner A., Adkins C.B., Zhang Y., Taupitz M., Halpern E.F., McDougal W.S., Wu C.L., Cheng L.L. Retrospective analysis ofprostate cancer recurrence potential with tissue metabolomic profiles. Prostate. 2010. V. 70. no. 7. P.710-717.
30. Tayari N., Wright A.J., Heerschap A. Absolute choline tissue concentration mapping for prostate cancer localization and characterization using 3D 1 H MRSI without water-signal suppression. Magn. Reson. Med. 2022. V. 87. no. 2. P. 561-
31. Gholizadeh N., Greer P.B., Simpson J., Goodwin J., Fu C., Lau P., Siddique S., Heerschap A., Ramadan S. Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection. J. Biomed. Sci. 2021. V. 28. no. 1. P. 54-62.
32. Xu Z., Wang Y., Xiao Z.G., Zou C., Zhang X., Wang Z., Wu D., Yu S., Chan F.L. Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer. Oncogene. 2018. V. 37. no. 48. P. 6259-6274.
33. Аполихин О.И., Сивков А.В., Ефремов Г.Д., Михайленко Д.С., Шадеркин И.А., Войтко Д.А., Просянников М.Ю., Григорьева М.В. PSA3 pc3 и TMPSS2-ERG в диагностике рака предстательной железы: первый опыт применения комбинации маркеров в России // Экспериментальная и клиническая урология 2015. №2. C.30-36.
34. Hansen A.F., Sandsmark E., Rye M.B., Wright A.J., Bertilsson H., Richardsen E., Viset T., Bofin A.M., Angelsen A., Selnaes K.M. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer. Oncotarget. 2016. V. 7. no. 27. P. 42071-42085.
35. Braadland P.R., Giskeodegard G., Sandsmark E., Bertilsson H., Euceda L.R., Hansen A.F., Guldvik I.J., Selnaes K.M., Grytli H.H., Katz B. Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. Br. J. Cancer 2017. V. 117. no. 11. P. 1656-1664.
36. Soylu H., Unal B., Aksu K., Avci S., Caylan A.E. Ustunel I Evaluation of angiogenic apelin/apelin receptor axis in normal prostate, high grade prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Malays J. Pathol. 2022. V. 44. no. 3. P.461-467.
37. Cohen R.J., Beales M.P., McNeal J.E. Prostate secretory granules in normal and neoplastic prostate glands: a diagnostic aid to needle biopsy. Hum Pathol. 2000. V. 31. no. 12. P. 1515-1519.
38. Frankcombe D.E., Li J., Cohen R.J. Redefining the Concept of Clinically Insignificant Prostate Cancer. Urology. 2020. V. 136. no. 2. P. 176-179.
39. Lima A.R., Bastos Mde L., Carvalho M., Guedes de Pinho P. Biomarker Discovery in Human Prostate Cancer: An Update in Metabolomics Studies. Transl. Oncol. 2016. V. 9. no. 3. P. 357-370.
40. Jupin M., van Heijster F.H.A., Heerschap A. Metabolite interactions in prostatic fluid mimics assessed by 1H NMR. MAGMA. 2022. V. 35. no. 4. P. 683-694.
41. Kurihara S. Polyamine metabolism and transport in gut microbes. Biosci Biotechnol Biochem. 2022. V. 86. no. 8. P. 957-966.
42. Cipolla B., Moulinoux J.P., Quemener V., Havouis R., Martin L.A., Guille F., Lobel B. Erythrocyte polyamine levels in human prostatic carcinoma. J. Urol. 1990. V. 144. no. 5. P. 1164-1166.
43. Cipolla B., Guille F., Moulinoux J.P., Bansard J.Y., Roth S., Staerman F., Corbel L., Quemener V., Lobel B. Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J. Urol. 1994.V. 151. no. 3. P. 629-633
44. Cipolla B.G., Ziade J., Bansard J.Y., Moulinoux J.P., Staerman F., Quemener V., Lobel B., Guille F. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with Ml prostate carcinoma. Cancer. 1996. V. 78. no. 5. P.1055-1065.